OBJECTIVES: Corifollitropin alfa, a fusion protein, has a longer elimination half-life and extended time to peak levels than recombinant FSH (rFSH). The main aim of this study was to perform comparative pharmacoeconomic analysis of using korifollitropin alfa with ganirelix and follitropin alfa with cetrorelix for ovarian stimulation.  METHODS: Analysis of the published clinical trials was conducted to evaluate comparative efficacy and safety of the studied therapy options. Direct medical costs included drug therapy and hospital treatment. Taking into account the hypothesis of equal effectiveness of using korifollitropin alfa with ganirelix and follitropin alfa with cetrorelix for ovarian stimulation for pharmacoeconomic analysis was chosen “cost minimization” analysis (CMA). Direct medical costs were calculated for 1 patient. In this study were performed 2 variants of ovarian stimulation costs, in 1^st variant was compared only korifollitropin alfa with ganirelix and follitropin alfa with cetrorelix, in 2^ndvariant - korifollitropin alfa plus follitropin beta with ganirelix and follitropin alfa with cetrorelix. RESULTS: According to published trials corifollitropin alfa was a novel and effective treatment option for potential normal responder patients undergoing ovarian stimulation with gonadotropin co-treatment resulting in a high ongoing pregnancy rate, equal to that achieved with daily rFSH. The average cost for 1^st variant of a course of korifollitropin alfa with ganirelix was 34 285 rubles ($ 640), and follitropin alfa with cetrorelix – 65 352 rubles ($ 1 220). The average cost for 2^nd variant of a course of korifollitropin alfa plus follitropin beta with ganirelix was 66 886 rubles ($ 1 249), and follitropin alfa with cetrorelix – 65 352 rubles ($ 1 220). The CMA has shown that annual savings when used for ovarian stimulation 1^stvariant without follitropin beta will be 18%. CONCLUSIONS: The using for ovarian stimulation korifollitropin alfa with ganirelix was more economically justified treatment option.